Form 4: Rigel Pharmaceuticals Director Mark Frohlich Reports Acquisition of Shares and Stock Options

Rigel Pharmaceuticals Director Mark W. Frohlich has reported the acquisition of 1,250 shares of common stock through a Restricted Stock Unit award and 1,500 stock options, aligning his interests with the company's performance.

Summary

• Director Mark W. Frohlich acquired 1,250 shares of Rigel Pharmaceuticals Common Stock on May 23, 2025.
• These shares are from a Restricted Stock Unit (RSU) award, granted at a price of $0, and will fully vest on the date prior to the company's next Annual Meeting, subject to his continuous service on the Board of Directors.
• Mr. Frohlich also acquired 1,500 stock options on May 23, 2025, with an exercise price of $18.95, granted at a price of $0.
• These stock options will vest monthly over one year from the grant date (May 23, 2025), also contingent on his continuous service on the Board, and have an expiration date of May 23, 2035.
• Following these transactions, Mr. Frohlich beneficially owns 1,250 shares of common stock and 1,500 stock options directly.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it indicates a director receiving equity compensation, aligning their interests with the company's long-term performance. It's a routine, expected event for insider compensation and generally viewed favorably by the market as it signals commitment.

Positives

• The acquisition of shares and stock options by a director aligns management's interests with shareholder value, incentivizing long-term performance.
• Grants of equity awards are a common and expected form of compensation for directors, indicating continued commitment to the company.

Risks

• The vesting of both the Restricted Stock Units and stock options is contingent upon the Reporting Person's continuous service on the Company's Board of Directors, meaning the awards could be forfeited if service ceases.

Future Outlook

The document does not provide a future outlook for the company's performance or strategy, as it is a transactional report focused solely on an insider's equity transactions.

Industry Context

This Form 4 filing details a routine equity grant to a director, which is a common practice in the biotechnology and pharmaceutical industry. Such grants are standard forms of executive and director compensation, designed to align the long-term interests of company leadership with shareholder value and company performance.

Comparison to Industry Standards

• The granting of Restricted Stock Units (RSUs) and stock options to directors is a standard compensation practice across the biotechnology and pharmaceutical sectors, comparable to structures observed at companies like Gilead Sciences, Amgen, or Biogen.
• The vesting schedules, with RSUs vesting prior to the next Annual Meeting and options vesting monthly over one year, are typical for director compensation, aiming to ensure retention and align interests over a defined period.
• The exercise price of $18.95 for the stock options would be assessed against the market price of RIGL stock on the grant date, a common method to determine if the options were granted at-the-money, in-the-money, or out-of-the-money, consistent with industry norms.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with the company's long-term stock performance, potentially encouraging decisions that enhance shareholder value.
• Employees: No direct impact on general employees is mentioned in this filing.

Next Steps

• The Restricted Stock Units are expected to fully vest on the date prior to the Company's next Annual Meeting.
• The stock options will vest monthly over one year from the grant date of May 23, 2025.

Key Dates

Recommendation

Keywords

Rigel Pharmaceuticals, RIGL, SEC Form 4, Insider Transaction, Stock Options, Restricted Stock Units, Director Compensation, Equity Awards, Beneficial Ownership